A prospective, randomized, multi-center, open-label, comparative safety and efficacy study of prophylactically administered pegylated interferon alfa-2a (Pegasys) [peginterferon alfa-2a] plus ribavirin vs. no prophylaxis following liver transplantation for hepatitis C

Trial Profile

A prospective, randomized, multi-center, open-label, comparative safety and efficacy study of prophylactically administered pegylated interferon alfa-2a (Pegasys) [peginterferon alfa-2a] plus ribavirin vs. no prophylaxis following liver transplantation for hepatitis C

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2011

At a glance

  • Drugs Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 May 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 26 Jan 2010 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 26 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top